Lilly to Present Phase 3 Data at AAN 2018 Reinforcing Commitment to New, Innovative Therapies in Migraine

April 20, 2018 | By forimmediaterele | Filed in: Press Releases.

Travel & Tourism Industry release:

INDIANAPOLIS, April 20, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today it will present Phase 3 data for galcanezumab and lasmiditan, two investigational treatments for migraine, at the American Academy of Neurology (AAN) annual meeting taking place April 21-27 in Los Angeles.

Click here to read the full release with contact information on PR Newswire. Some releases are not in English.

To post and circulate your own press release on FIR and the eTN Network  please click here 


Comments are closed here.